Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Warren Buffett Owns This Big Data Stock: Should You?

Verisk Analytics  (NASDAQ: VRSK  ) isn't a sexy stock, and it doesn't attract a lot of media hype, but it's a steadily growing big data company Warren Buffett has owned for years.

As the country exited the financial crisis In 2009, Buffett and Verisk's other insurance company owners, including Hartford Insurance and AIG, decided to spin off Verisk to raise money to support their struggling balance sheets.

But Buffett's Berkshire Hathaway  (NYSE: BRK-A  ) (NYSE: BRK-B  )  was the only pre-IPO owner not to sell into Verisk's IPO, and Buffett still owns 1.5 million Verisk shares as of December. So, let's take a look at why Mr. Buffett remains a fan of this data crunching company. 

VRSK Chart

VRSK data by YCharts.

Born from insurers
In the insurance business, it's all about identifying and pricing risk. The better able you are to figure out whether a claim will be filed, the better able you are to price insurance for a profit. Verisk's data mining solutions do that every day for all 100 of the largest U.S. property & casualty insurers. Those 100 insurers make up 85% of the $540 billion in P&C premiums written last year.

Verisk's roots stretch back to 1971, when a consortium of insurers decided they could get better answers cheaper by combining their data analysis efforts. Over the years, savvy acquisitions and product development expanded Verisk's product offering to include underwriting, claims management, compliance, and portfolio analysis, too. The combination of more services and a top-shelf customer base has allowed Verisk's insurance business to grow by a compounded 9% annually over the past decade. 

Source: Investor Presentation.

Expanding into health care
While the majority of Verisk's revenue continues to come from the insurance market, Verisk's abilitiy to compile, crunch, and conveniently report data is resonating with other industries, too.

Increasingly, practices and processes that were formerly driven by empirical -- and highly subjective -- estimates are migrating to quantitative analysis. As a result, Verisk's products and services appeal to financial services companies like credit card issuers as well as health care companies, including insurers and providers.

Verisk's push into health care has been particularly impressive. Many health care participants face business challenges similar to the P&C market, particularly health care payers like insurance companies and self-insured Fortune 500 firms.

Despite a short history of serving the health care industry, 232 health care payers have already signed on with Verisk, including 9 of the top 10 insurance plans.

Another 26 health care providers, including physician networks, as well as 61 employers, have inked deals with Verisk to help them with claims, risk modeling, Medicare Advantage risk adjustment, and quality auditing.

That demand has sparked Verisk's health care sales, driving them up from just $50 million in 2009 to more than $270 million in 2013. That's impressive, but it only hints at the larger market potential, which Verisk estimates exceeds $4 billion annually.

Of course, Verisk isn't the only one trying to work with health care companies. Verisk competes directly with United Healthcare's  (NYSE: UNH  ) OptumInsight, a company that offers a suite of analytic and consulting services to health care players.

United's position as the largest U.S. health insurance company has given OptumInsight immediate cache, helping OptumInsight build a backlog north of $5.5 billion exiting 2013. United expects $2.7 billion of OptumInsight's backlog will be realized this year, of which roughly $1 billion is tied to other United companies. Even considering the inter-business sales, OptumInsight is still arguably Verisk's stiffest competitor in the health care sector. 

McKesson  (NYSE: MCK  ) Technology Group is another Verisk competitor. McKesson's client list includes more than 50% of all health systems and 76% of health systems with more than 200 beds, giving McKesson's Business Performance Services business opportunities to cross-sell consulting services and products like McKesson Analytics Advisor. Overall, McKesson's Technology Group posted sales of $738 million in the fourth quarter, nearly $600 million of which came from services.

Fool-worthy final thoughts
Verisk's Buffet-appeal isn't limited to the competitive advantage it maintains thanks to Verisk's large and growing datasets. It's also tied to the businesses' highly attractive -- and profit-friendly -- ability to build a product once, and sell it many times.

Whether Verisk can remain differentiated enough to outpace United Healthcare's Optum and McKesson is a question still to be answered. All three companies are increasingly going to bang into one another in board rooms as the industry grapples with improving care and reducing costs post reform.

However, since all industries are eager to boost profitability, it would seem Verisk may find it has long-term opportunity that stretches far beyond where it sits currently.

And that rings true with the greatest thing Warren Buffett ever said
Warren Buffett has made billions through his investing, and he wants you to be able to invest like him. Through the years, Buffett has offered up investing tips to shareholders of Berkshire Hathaway. Now you can tap into the best of Warren Buffett's wisdom in a new special report from The Motley Fool. Click here now for a free copy of this invaluable report.

Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 13, 2014, at 10:29 AM, Interventizio wrote:

    Good job in pointing out this stock. Unfortunately, I think it's considerably overvalued if you consider the historical P/E data.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2908393, ~/Articles/ArticleHandler.aspx, 8/31/2015 11:24:42 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Todd Campbell

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Today's Market

updated Moments ago Sponsored by:
DOW 16,499.43 -143.58 -0.86%
S&P 500 1,973.03 -15.84 -0.80%
NASD 4,789.98 -38.35 -0.79%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 11:07 AM
VRSK $73.40 Down -0.54 -0.73%
Verisk Analytics CAPS Rating: *****
BRK-A $201980.00 Down -3364.00 -1.64%
Berkshire Hathaway… CAPS Rating: ****
BRK-B $133.57 Down -2.17 -1.60%
Berkshire Hathaway CAPS Rating: *****
MCK $198.21 Down -2.59 -1.29%
McKesson CAPS Rating: *****
UNH $116.01 Down -1.27 -1.08%
UnitedHealth Group CAPS Rating: *****